Literature DB >> 22677187

Development of antigen cross-presentation capacity in dendritic cells.

Christiane Dresch1, Yann Leverrier, Jacqueline Marvel, Ken Shortman.   

Abstract

Cross-presentation by dendritic cells (DCs) of exogenous antigens on MHC class I is important for the generation of immune responses to intracellular pathogens, as well as for maintenance of self tolerance. In mice, the CD8(+) DC lineage is specialised for this role. However, DCs of this lineage are not born with cross-presentation capacity. Several studies have demonstrated that it must be induced as a later developmental step by cytokines such as granulocyte macrophage colony-stimulating factor (GM-CSF), or by microbial products such as toll-like receptor (TLR) ligands. Increased cross-presentation capacity is thus induced in peripheral CD8 lineage DCs during inflammation or infection. However, this capacity is already fully developed in steady-state thymic CD8(+) DCs, in accordance with their role in the deletion of self-reactive developing T cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677187     DOI: 10.1016/j.it.2012.04.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  33 in total

1.  How does batf3 determine dendritic cell development?

Authors:  Ken Shortman
Journal:  Immunol Cell Biol       Date:  2015-08-25       Impact factor: 5.126

2.  EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.

Authors:  Shaorong Yu; Huanhuan Sha; Xiaobing Qin; Yan Chen; Xiaoyou Li; Meiqi Shi; Jifeng Feng
Journal:  Oncogene       Date:  2020-01-30       Impact factor: 9.867

3.  Crucial role of plasmacytoid dendritic cells in the development of acute colitis through the regulation of intestinal inflammation.

Authors:  K Arimura; H Takagi; T Uto; T Fukaya; T Nakamura; N Choijookhuu; Y Hishikawa; Y Yamashita; K Sato
Journal:  Mucosal Immunol       Date:  2016-11-16       Impact factor: 7.313

4.  Plasmacytoid Dendritic Cells Require Direct Infection To Sustain the Pulmonary Influenza A Virus-Specific CD8 T Cell Response.

Authors:  Emily A Hemann; Louisa E Sjaastad; Ryan A Langlois; Kevin L Legge
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

5.  The Trypanosoma brucei gambiense secretome impairs lipopolysaccharide-induced maturation, cytokine production, and allostimulatory capacity of dendritic cells.

Authors:  Edwin Garzón; Philippe Holzmuller; Rachel Bras-Gonçalves; Philippe Vincendeau; Gérard Cuny; Jean Loup Lemesre; Anne Geiger
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

Review 6.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

7.  Engaging adaptive immunity with biomaterials.

Authors:  Carolina Mora-Solano; Joel H Collier
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

8.  RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

Authors:  P Duewell; A Steger; H Lohr; H Bourhis; H Hoelz; S V Kirchleitner; M R Stieg; S Grassmann; S Kobold; J T Siveke; S Endres; M Schnurr
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

9.  Medullary thymic epithelial cells and CD8α+ dendritic cells coordinately regulate central tolerance but CD8α+ cells are dispensable for thymic regulatory T cell production.

Authors:  Olivier Herbin; Anthony J Bonito; Seihwan Jeong; Erica G Weinstein; Adeeb H Rahman; Huabao Xiong; Miriam Merad; Konstantina Alexandropoulos
Journal:  J Autoimmun       Date:  2016-08-16       Impact factor: 7.094

10.  Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.

Authors:  Emily A Hemann; Sang-Moo Kang; Kevin L Legge
Journal:  J Immunol       Date:  2013-07-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.